Ιωάννη Κρανιδιώτη 2

555 35, Πυλαία, Θεσσαλονίκη

+30 2310 475 662

Καθημερινές : 9:00 - 14:00

info@hcds.gr

https://hcds.gr/epikoinonia/

Αναστολείς ρενίνης-υποδοχέων αγγειοτενσίνης-αλδοστερόνης και COVID-19

the NEW ENGLAND JOURNAL of MEDICINE

Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19

Muthiah Vaduganathan, M.D., M.P.H.,
Orly Vardeny, Pharm.D.,
Thomas Michel, M.D., Ph.D.,
John J.V. McMurray, M.D.,
Marc A. Pfeffer, M.D., Ph.D.,
and Scott D. Solomon,


Τhe renin–angiotensin–aldosterone system (RAAS) is an elegant cascade of vasoactive peptides that orchestrate key processes in human physiology. Severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1) and SARS-CoV-2, which have been responsible for the SARS epidemic in 2002 to 2004 and for the more recent coronavirus disease 2019 (Covid-19) pandemic, respectively, interface with the RAAS through angiotensin-converting enzyme 2 (ACE2), an enzyme that physiologically counters RAAS activation but also functions as a receptor for both SARS viruses.1,2 The interaction between the SARS viruses and ACE2 has been proposed as a potential factor in their infectivity,3,4 and there are concerns about the use of RAAS inhibitors that may alter ACE2 and whether variation in ACE2 expression may be in part responsible for disease virulence in the ongoing Covid-19 pandemic.5-8 Indeed, some media sources and health systems have recently called for the discontinuation of ACE inhibitors and angiotensin-receptor blockers (ARBs), both prophylactically and in the context of suspected Covid-19.

continue reading  at NEJM

Σχολιάστε

Αυτός ο ιστότοπος χρησιμοποιεί το Akismet για να μειώσει τα ανεπιθύμητα σχόλια. Μάθετε πώς υφίστανται επεξεργασία τα δεδομένα των σχολίων σας.

στοιχεία σύνδεσης

Kατηγορίες

Recent Posts

Ιστορικό

κοινοποιήστε στο :

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on pinterest
Pinterest
Share on skype
Skype
Share on email
Email